Ceramides and sphingomyelinases in senile plaques

Neurobiology of Disease

Volumn 65, Issue , 2014, Pages 193-201

  Panchal, Maï ^a,b   Gaudin, Mathieu ^c,d   Lazar, Adina N ^a,b,g   Salvati, Elisa ^e   Rivals, Isabelle ^f   Ayciriex, Sophie ^c   Dauphinot, Luce ^b   Dargère, Delphine ^c   Auzeil, Nicolas ^c   Masserini, Massimo ^e   Laprévote, Olivier ^c,h   Duyckaerts, Charles ^a,b,g  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^d INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g PSL RESEARCH UNIVERSITY   (France)

^h HÔPITAL LARIBOISIÈRE   (France)

Author keywords

A peptide; Alzheimer disease; Ceramides; Laser microdissection; Lipidomics; Lipids; Mass spectrometry; Senile plaques; Sphingomyelinase

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CERAMIDE; GALACTOSYLCERAMIDE; LIPIDOME; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

AGED; ALZHEIMER DISEASE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME SYNTHESIS; FLUORESCENCE ANALYSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LASER MICRODISSECTION; LIPID ANALYSIS; LIPIDOMICS; MALE; NEUROPIL; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; SENILE PLAQUE; SURFACE PLASMON RESONANCE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VERY ELDERLY;

ALZHEIMER DISEASE; AΒ PEPTIDE; CERAMIDES; LASER MICRODISSECTION; LIPIDOMICS; LIPIDS; MASS SPECTROMETRY; SENILE PLAQUES; SPHINGOMYELINASE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; CERAMIDES; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MICRODISSECTION; MIDDLE AGED; PLAQUE, AMYLOID; SPHINGOMYELIN PHOSPHODIESTERASE; SURFACE PLASMON RESONANCE;

EID: 84896737290     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.01.010     Document Type: Article

References (50)

1. Bandaru V.V., Troncoso J., Wheeler D., Pletnikova O., Wang J., Conant K., et al. ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain. Neurobiol. Aging 2009, 591-599.
2. Basak J.M., Verghese P.B., Yoon H., Kim J., Holtzman D.M. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Abeta uptake and degradation by astrocytes. J. Biol. Chem. 2012, 287(17):13959-13971.
3. Benilova I., Karran E., De Strooper B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 2012, 15(3):349-357.
4. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 2007, 39(1):17-23.
5. Braak H., Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991, 82(4):239-259.
6. Elipidomic analysis using a shotgun approach and its application to biomarker detection and identification in osteoarthritis patients. J. Proteome Res. 2010, 9(5):2377-2389.
7. Cossec J.C., Simon A., Marquer C., Moldrich R.X., Leterrier C., Rossier J., et al. Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to the level of plasma membrane cholesterol. Biochim. Biophys. Acta 2010, 1801(8):846-852.
8. Cutler R.G., Kelly J., Storie K., Pedersen W.A., Tammara A., Hatanpaa K., et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(7):2070-2075.
9. Delaere P., Duyckaerts C., Masters C., Beyreuther K., Piette F., Hauw J.J. Large amounts of neocortical beta A4 deposits without neuritic plaques nor tangles in a psychometrically assessed, non-demented person. Neurosci. Lett. 1990, 116(1-2):87-93.
10. Dickson D.W., Crystal H.A., Mattiace L.A., Masur D.M., Blau A.D., Davies P., et al. Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 1992, 13(1):179-189.
11. Duyckaerts C., Delatour B., Potier M.C. Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 2009, 118(1):5-36.
12. Fahy E., Subramaniam S., Brown H.A., Glass C.K., Merrill A.H., Murphy R.C., et al. A comprehensive classification system for lipids. J. Lipid Res. 2005, 46(5):839-861.
13. Fahy E., Subramaniam S., Murphy R.C., Nishijima M., Raetz C.R., Shimizu T., et al. Update of the LIPID MAPS comprehensive classification system for lipids. J. Lipid Res. 2009, 50:S9-S14. (Suppl.).
14. Filippov V., Song M.A., Zhang K., Vinters H.V., Tung S., Kirsch W.M., et al. Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J. Alzheimers Dis. 2012, 29(3):537-547.
15. Gaudin M., Panchal M., Auzeil N., Duyckaerts C., Brunelle A., Laprevote O., et al. Choline-containing phospholipids in microdissected human Alzheimer's disease brain senile plaque versus neuropil. Bioanalysis 2012, 4(17):2153-5159.
16. Gobbi M., Re F., Canovi M., Beeg M., Gregori M., Sesana S., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010, 31(25):6519-6529.
17. Goni F.M., Alonso A. Sphingomyelinases: enzymology and membrane activity. FEBS Lett. 2002, 531(1):38-46.
18. Gottfries C.G., Jungbjer B., Karlsson I., Svennerholm L. Reductions in membrane proteins and lipids in basal ganglia of classic Alzheimer disease patients. Alzheimer Dis. Assoc. Disord. 1996, 10(2):77-81.
19. Grimm M.O., Grimm H.S., Patzold A.J., Zinser E.G., Halonen R., Duering M., et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 2005, 7(11):1118-1123.
20. Han X., Holtzman M.H, McKeel D.W., Kelley J., Morris J.C. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis. J. Neurochem. 2002, 82(4):809-818.
21. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297(5580):353-356.
22. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41(10):1088-1093.
23. Hashimoto T., Serrano-Pozo A., Hori Y., Adams K.W., Takeda S., Banerji A.O., et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 2012, 32(43):15181-15192.
24. Haughey N.J., Cutler R.G., Tamara A., McArthur J.C., Vargas D.L., Pardo C.A., et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 2004, 55(2):257-267.
25. He X., Huang Y., Li B., Gong C.X., Schuchman E.H. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurobiol. Aging 2010, 31(3):398-408.
26. Jana A., Pahan K. Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J. Biol. Chem. 2004, 279(49):51451-51459.
27. Katsel P., Li C., Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease?. Neurochem. Res. 2007, 32(4-5):845-856.
28. Lazar A.N., Mourtas S., Youssef I., Parizot C., Dauphin A., Delatour B., et al. Curcumin-conjugated nanoliposomes with high affinity for Abeta deposits: possible applications to Alzheimer disease. Nanomedicine 2013, 9(5):712-721.
29. Lazar A.N., Bich C., Panchal M., Desbenoit N., Petit V.W., Touboul D., et al. Time-of-flight secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol overload in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol. 2013, 125(1):133-144.
30. Liao L., Cheng D., Wang J., Duong D.M., Losik T.G., Gearing M., et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 2004, 279(35):37061-37068.
31. Malaplate-Armand C., Florent-Bechard S., Youssef I., Koziel V., Sponne I., Kriem B., et al. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiol. Dis. 2006, 23(1):178-189.
32. Martin S.F., Sawai H., Villalba J.M., Hannun Y.A. Redox regulation of neutral sphingomyelinase-1 activity in HEK293 cells through a GSH-dependent mechanism. Arch. Biochem. Biophys. 2007, 459(2):295-300.
33. Megha, Sawatzki P., Kolter T., Bittman R., London E. Effect of ceramide N-acyl chain and polar headgroup structure on the properties of ordered lipid domains (lipid rafts). Biochim. Biophys. Acta 2007, 1768(9):2205-2212.
34. Meyer-Luehmann M., Coomaraswamy J., Bolmont T., Kaeser S., Schaefer C., Kilger E., et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006, 313(5794):1781-1784.
35. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?. Neuromolecular Med. 2010, 12(4):331-340.
36. Mintun M.A., Larossa G.N., Sheline Y.I., Dence C.S., Lee S.Y., Mach R.H., et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67(3):446-452.
37. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41(4):479-486.
38. Panchal M., Loeper J., Cossec J.C., Perruchini C., Lazar A., Pompon D., et al. Enrichment of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by mass spectrometry. J. Lipid Res. 2010, 51(3):598-605.
39. Pinto S.N., Silva L.C., Futerman A.H., Prieto M. Effect of ceramide structure on membrane biophysical properties: the role of acyl chain length and unsaturation. Biochim. Biophys. Acta 2011, 1808(11):2753-2760.
40. Puglielli L., Ellis B.C., Saunders A.J., Kovacs D.M. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. J. Biol. Chem. 2003, 278(22):19777-19783.
41. Rudinskiy N., Hawkes J.M., Betensky R.A., Eguchi M., Yamaguchi S., Spires-Jones T.L., et al. Orchestrated experience-driven Arc responses are disrupted in a mouse model of Alzheimer's disease. Nat. Neurosci. 2012, 15(10):1422-1429.
42. Satoi H., Tomimoto H., Ohtani R., Kitano T., Kondo T., Watanabe M., et al. Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. Neuroscience 2005, 130(3):657-666.
43. Smith C.A., O'Maille G., Want E.J., Qin C., Trauger S.A., Brandon T.R., et al. METLIN: a metabolite mass spectral database. Ther. Drug Monit. 2005, 27(6):747-751.
44. Smith C.A., Want E.J., O'Maille G., Abagyan R., Siuzdak G. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal. Chem. 2006, 78(3):779-787.
45. Soderberg M., Edlund C., Alafuzoff I., Kristensson K., Dallner G. Lipid composition in different regions of the brain in Alzheimer's disease/senile dementia of Alzheimer's type. J. Neurochem. 1992, 59(5):1646-1653.
46. Strittmatter W.J., Saunders A.M., Schmechel D., Pericak-Vance M., Enghild J., Salvesen G.S., et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1993, 90(5):1977-1981.
47. Thal D.R., Rub U., Orantes M., Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002, 58(12):1791-1800.
48. Thevissen K., Francois I.E., Winderickx J., Pannecouque C., Cammue B.P. Ceramide involvement in apoptosis and apoptotic diseases. Mini Rev. Med. Chem. 2006, 6(6):699-709.
49. Venkataraman K., Futerman A.H. Ceramide as a second messenger: sticky solutions to sticky problems. Trends Cell Biol. 2000, 10(10):408-412.
50. Wolf H., Hensel A., Arendt T., Kivipelto M., Winblad B., Gertz H.J. Serum lipids and hippocampal volume: the link to Alzheimer's disease?. Ann. Neurol. 2004, 56(5):745-748.